36: Reproductive Health Drugs
- Page ID
- 90350
\( \newcommand{\vecs}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)
\( \newcommand{\vecd}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash {#1}}} \)
\( \newcommand{\dsum}{\displaystyle\sum\limits} \)
\( \newcommand{\dint}{\displaystyle\int\limits} \)
\( \newcommand{\dlim}{\displaystyle\lim\limits} \)
\( \newcommand{\id}{\mathrm{id}}\) \( \newcommand{\Span}{\mathrm{span}}\)
( \newcommand{\kernel}{\mathrm{null}\,}\) \( \newcommand{\range}{\mathrm{range}\,}\)
\( \newcommand{\RealPart}{\mathrm{Re}}\) \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\)
\( \newcommand{\Argument}{\mathrm{Arg}}\) \( \newcommand{\norm}[1]{\| #1 \|}\)
\( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\)
\( \newcommand{\Span}{\mathrm{span}}\)
\( \newcommand{\id}{\mathrm{id}}\)
\( \newcommand{\Span}{\mathrm{span}}\)
\( \newcommand{\kernel}{\mathrm{null}\,}\)
\( \newcommand{\range}{\mathrm{range}\,}\)
\( \newcommand{\RealPart}{\mathrm{Re}}\)
\( \newcommand{\ImaginaryPart}{\mathrm{Im}}\)
\( \newcommand{\Argument}{\mathrm{Arg}}\)
\( \newcommand{\norm}[1]{\| #1 \|}\)
\( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\)
\( \newcommand{\Span}{\mathrm{span}}\) \( \newcommand{\AA}{\unicode[.8,0]{x212B}}\)
\( \newcommand{\vectorA}[1]{\vec{#1}} % arrow\)
\( \newcommand{\vectorAt}[1]{\vec{\text{#1}}} % arrow\)
\( \newcommand{\vectorB}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)
\( \newcommand{\vectorC}[1]{\textbf{#1}} \)
\( \newcommand{\vectorD}[1]{\overrightarrow{#1}} \)
\( \newcommand{\vectorDt}[1]{\overrightarrow{\text{#1}}} \)
\( \newcommand{\vectE}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash{\mathbf {#1}}}} \)
\( \newcommand{\vecs}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)
\( \newcommand{\vecd}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash {#1}}} \)
\(\newcommand{\avec}{\mathbf a}\) \(\newcommand{\bvec}{\mathbf b}\) \(\newcommand{\cvec}{\mathbf c}\) \(\newcommand{\dvec}{\mathbf d}\) \(\newcommand{\dtil}{\widetilde{\mathbf d}}\) \(\newcommand{\evec}{\mathbf e}\) \(\newcommand{\fvec}{\mathbf f}\) \(\newcommand{\nvec}{\mathbf n}\) \(\newcommand{\pvec}{\mathbf p}\) \(\newcommand{\qvec}{\mathbf q}\) \(\newcommand{\svec}{\mathbf s}\) \(\newcommand{\tvec}{\mathbf t}\) \(\newcommand{\uvec}{\mathbf u}\) \(\newcommand{\vvec}{\mathbf v}\) \(\newcommand{\wvec}{\mathbf w}\) \(\newcommand{\xvec}{\mathbf x}\) \(\newcommand{\yvec}{\mathbf y}\) \(\newcommand{\zvec}{\mathbf z}\) \(\newcommand{\rvec}{\mathbf r}\) \(\newcommand{\mvec}{\mathbf m}\) \(\newcommand{\zerovec}{\mathbf 0}\) \(\newcommand{\onevec}{\mathbf 1}\) \(\newcommand{\real}{\mathbb R}\) \(\newcommand{\twovec}[2]{\left[\begin{array}{r}#1 \\ #2 \end{array}\right]}\) \(\newcommand{\ctwovec}[2]{\left[\begin{array}{c}#1 \\ #2 \end{array}\right]}\) \(\newcommand{\threevec}[3]{\left[\begin{array}{r}#1 \\ #2 \\ #3 \end{array}\right]}\) \(\newcommand{\cthreevec}[3]{\left[\begin{array}{c}#1 \\ #2 \\ #3 \end{array}\right]}\) \(\newcommand{\fourvec}[4]{\left[\begin{array}{r}#1 \\ #2 \\ #3 \\ #4 \end{array}\right]}\) \(\newcommand{\cfourvec}[4]{\left[\begin{array}{c}#1 \\ #2 \\ #3 \\ #4 \end{array}\right]}\) \(\newcommand{\fivevec}[5]{\left[\begin{array}{r}#1 \\ #2 \\ #3 \\ #4 \\ #5 \\ \end{array}\right]}\) \(\newcommand{\cfivevec}[5]{\left[\begin{array}{c}#1 \\ #2 \\ #3 \\ #4 \\ #5 \\ \end{array}\right]}\) \(\newcommand{\mattwo}[4]{\left[\begin{array}{rr}#1 \amp #2 \\ #3 \amp #4 \\ \end{array}\right]}\) \(\newcommand{\laspan}[1]{\text{Span}\{#1\}}\) \(\newcommand{\bcal}{\cal B}\) \(\newcommand{\ccal}{\cal C}\) \(\newcommand{\scal}{\cal S}\) \(\newcommand{\wcal}{\cal W}\) \(\newcommand{\ecal}{\cal E}\) \(\newcommand{\coords}[2]{\left\{#1\right\}_{#2}}\) \(\newcommand{\gray}[1]{\color{gray}{#1}}\) \(\newcommand{\lgray}[1]{\color{lightgray}{#1}}\) \(\newcommand{\rank}{\operatorname{rank}}\) \(\newcommand{\row}{\text{Row}}\) \(\newcommand{\col}{\text{Col}}\) \(\renewcommand{\row}{\text{Row}}\) \(\newcommand{\nul}{\text{Nul}}\) \(\newcommand{\var}{\text{Var}}\) \(\newcommand{\corr}{\text{corr}}\) \(\newcommand{\len}[1]{\left|#1\right|}\) \(\newcommand{\bbar}{\overline{\bvec}}\) \(\newcommand{\bhat}{\widehat{\bvec}}\) \(\newcommand{\bperp}{\bvec^\perp}\) \(\newcommand{\xhat}{\widehat{\xvec}}\) \(\newcommand{\vhat}{\widehat{\vvec}}\) \(\newcommand{\uhat}{\widehat{\uvec}}\) \(\newcommand{\what}{\widehat{\wvec}}\) \(\newcommand{\Sighat}{\widehat{\Sigma}}\) \(\newcommand{\lt}{<}\) \(\newcommand{\gt}{>}\) \(\newcommand{\amp}{&}\) \(\definecolor{fillinmathshade}{gray}{0.9}\)- 36.0: Introduction
- This page covers human reproductive systems and related medications, detailing female processes like menstruation, contraception, labor, and menopause, while addressing male hormonal conditions and andropause. It highlights the distinction between gender identity and biological sex, clarifying that "female" and "male" pertain to biological characteristics linked to XX and XY chromosomes.
- 36.1: Review of the Female Reproductive System
- This page discusses the female reproductive system's structure and function, highlighting external and internal organs, hormonal regulation, and the menstrual cycle. It covers menopause, confirmed after 12 months without menstruation, typically occurring between the 30s and mid-50s, with symptoms like hot flashes and mood changes. It notes early menopause causes and concerns about decreased bone mass and fractures, indicating further exploration of these issues in later sections.
- 36.2: Hormonal, Contraception, and Infertility Drugs
- This page covers hormonal therapies, contraception, and infertility medications for female reproductive disorders. It details the characteristics, indications, adverse effects, and nursing considerations regarding hormonal drugs like estrogens and progestins. Various contraceptive methods—COCs, IUDs, and others—are discussed, stressing their benefits and potential side effects.
- 36.3: Uterine Motility Drugs and Lactation Considerations
- This page covers the use of uterine motility drugs during pregnancy and labor, focusing on oxytocics for stimulating contractions and tocolytics like magnesium sulfate to delay premature labor. It highlights important nursing implications, potential adverse reactions, and the need for careful monitoring, especially with drugs like mifepristone for pregnancy termination.
- 36.4: Bisphosphonates, Calcium Preparations, Vitamin D, and Estrogen Receptor Modulators
- This page discusses osteoporosis treatment, emphasizing bisphosphonates, calcium, vitamin D, and estrogen receptor modulators for postmenopausal women. It covers medication characteristics, side effects—such as osteonecrosis of the jaw for bisphosphonates and risks of venous thromboembolism for estrogen receptor modulators like raloxifene and toremifene.
- 36.5: Review of the Male Reproductive System
- This page details the male reproductive system's anatomy and functions, covering external and internal organs like the scrotum and testes. It explains sperm production, transportation, and the hormonal regulation involving testosterone, including its role in male development. The section also introduces andropause, discussing the effects of declining testosterone levels on male health with age.
- 36.6: Androgens, Antiandrogens, and Anabolic Steroids
- This page covers androgens, antiandrogens, and anabolic steroids for reproductive disorders, detailing their characteristics, uses, side effects, and nursing implications. Androgens like testosterone are crucial for male development; antiandrogens, such as bicalutamide, target advanced prostate cancer. Oxandrolone, an anabolic steroid, aids recovery and weight gain but poses serious risks.
- 36.7: Phosphodiesterase 5 Inhibitors
- This page discusses phosphodiesterase 5 (PDE5) inhibitors for erectile dysfunction, detailing how they improve blood flow by blocking the PDE5 enzyme. Key medications such as sildenafil, tadalafil, avanafil, and vardenafil are highlighted, along with their dosing and contraindications, particularly concerning nitrates due to hypotension risks.
- 36.8: Alpha Blockers and 5-Alpha-Reductase Inhibitors
- This page discusses the treatment of benign prostatic hyperplasia (BPH) with alpha blockers and 5-alpha-reductase inhibitors, detailing their mechanisms, side effects, and nursing implications such as patient assessment and education.
- 36.9: Chapter Summary
- This page discusses the male and female reproductive systems, emphasizing hormones and conditions across life stages. It details major ovarian and testicular hormones, hormonal drug use for low levels, cancer therapies, and menopause symptoms. Additionally, it covers medications for infertility, pregnancy, and menopause, including tocolytics, oxytocics, and hormone replacement therapies.
- 36.10: Key Terms
- This page discusses reproductive health medications and hormones, detailing categories such as 5-alpha-reductase inhibitors for BPH, abortifacients, and various contraceptives. It outlines key hormones like estrogen and progesterone, highlighting their roles in the menstrual cycle, pregnancy, and menopause. Furthermore, it addresses conditions such as hypogonadism and osteoporosis, as well as approaches for initiating contraception.
- 36.11: Review Questions
- This page discusses clinical scenarios necessitating nurses to prioritize assessment strategies and interventions tailored to clients' health issues. It underscores the significance of individualized care by considering medical history, medication interactions, and treatment side effects. Key priorities include evaluating symptoms from medication infusions, monitoring vital signs, and addressing medication-related risks.